Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Martiny-Baron

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Circulation Research|March 27, 2004
Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growthMartin Ehrbar, Valentin G Djonov, Christian Schnell, et al.
Structure (London, England : 1993)|February 14, 2006
Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificityJill E Chrencik, Alexei Brooun, Michael I Recht, et al.
The Journal of Biological Chemistry|March 23, 2005
Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organizationCornelia C Weber, Hao Cai, Martin Ehrbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitorHeidi A Lane, Jeanette M Wood, Paul M J McSheehy, et al.
Journal of Medicinal Chemistry|August 10, 2016
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase InhibitorsRalf Glatthar, Aleksandar Stojanovic, Thomas Troxler, et al.
Nature Medicine|March 6, 2012
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loopNicola Aceto, Nina Sausgruber, Heike Brinkhaus, et al.
Cancer Cell|March 31, 2004
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinaseCarlos García-Echeverría, Mark A Pearson, Andreas Marti, et al.
Journal of Medicinal Chemistry|December 3, 2015
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting AngiogenesisGuido Bold, Christian Schnell, Pascal Furet, et al.
Nature Communications|February 15, 2025
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologiesJuraj Velcicky, Gregor Cremosnik, Clemens Scheufler, et al.
Nature Communications|March 15, 2026
Single-cell and spatial profiling reveal cDC2A-CXCL13<sup>+</sup>CD8<sup>+</sup> T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planusRundong Jiang, Rachael Bogle, Xianying Xing, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Circulation Research|March 27, 2004
Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growthMartin Ehrbar, Valentin G Djonov, Christian Schnell, et al.
Structure (London, England : 1993)|February 14, 2006
Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificityJill E Chrencik, Alexei Brooun, Michael I Recht, et al.
The Journal of Biological Chemistry|March 23, 2005
Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organizationCornelia C Weber, Hao Cai, Martin Ehrbar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitorHeidi A Lane, Jeanette M Wood, Paul M J McSheehy, et al.
Journal of Medicinal Chemistry|August 10, 2016
Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase InhibitorsRalf Glatthar, Aleksandar Stojanovic, Thomas Troxler, et al.
Nature Medicine|March 6, 2012
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loopNicola Aceto, Nina Sausgruber, Heike Brinkhaus, et al.
Cancer Cell|March 31, 2004
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinaseCarlos García-Echeverría, Mark A Pearson, Andreas Marti, et al.
Journal of Medicinal Chemistry|December 3, 2015
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting AngiogenesisGuido Bold, Christian Schnell, Pascal Furet, et al.
Nature Communications|February 15, 2025
Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologiesJuraj Velcicky, Gregor Cremosnik, Clemens Scheufler, et al.
Nature Communications|March 15, 2026
Single-cell and spatial profiling reveal cDC2A-CXCL13<sup>+</sup>CD8<sup>+</sup> T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planusRundong Jiang, Rachael Bogle, Xianying Xing, et al.
Pageof 3